Last reviewed · How we verify
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal (REDUCE-MRSA)
The Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate MRSA (REDUCE MRSA) Trial is a cluster randomized trial of the comparative effectiveness of three strategies to prevent methicillin-resistant Staphylococcus aureus (MRSA) in intensive care units. The three strategies to be evaluated are: * screening on admission followed by isolation of MRSA+ patients * screening on admission followed by isolation and decolonization of MRSA+ patients * universal decolonization on admission with no screening. The decolonization regimen involves bathing with chlorhexidine plus intra-nasal application of mupirocin. The main outcome will be MRSA+ clinical cultures. The study is a partnership between the CDC, the CDC Prevention Epicenters, and the Hospital Corporation of America.
Details
| Lead sponsor | Harvard Pilgrim Health Care |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 74256 |
| Start date | 2009-09 |
| Completion | 2011-09 |
Conditions
- Methicillin-resistant Staphylococcus Aureus
Interventions
- Chlorhexidine bath and nasal mupirocin
Primary outcomes
- Main Outcome: Patients With Nosocomial MRSA Clinical Cultures — The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.
Hazard ratio for ICU-attributable MRSA+ clinical cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.
Countries
United States